PTPRC and colorectal carcinoma: These data suggest that the CD45high subpopulation exhibits a therapy-resistant phenotype and manages to survive through CRT, leading to an enrichment of the CD45high subpopulation and an increase in CD45 expression in remnant CRC cells after CRT.